Tesofensine

Tesofensine (NS2330) is an oral small-molecule inhibitor of presynaptic reuptake of dopamine, serotonin, and norepinephrine. It belongs to the phenyltropane chemical family. The Phase 3 Viking trial in 372 obese patients met its primary endpoint with approximately 10 percent weight loss over 24 weeks. The compound is not currently approved by any major regulator. Mexico's COFEPRIS declined approval in November 2024 after issuing a favorable technical opinion in 2023.

The drug was first developed by the Danish biotechnology company NeuroSearch in the early 2000s. Initial clinical work targeted Alzheimer's disease and Parkinson's disease, based on the rationale that increased monoamine availability could compensate for neurotransmitter deficits in those conditions. Efficacy in the neurological indications was insufficient for further development, but weight loss appeared consistently as an unintended effect, particularly in overweight and obese patients. NeuroSearch repurposed the program toward obesity and ran the TIPO-1 Phase 2 trial (Astrup et al., Lancet 2008), which reported approximately 10 percent weight loss at 0.5 mg/day over 24 weeks.

In 2014 the tesofensine program transferred to Saniona, a Danish CNS-focused biotech listed on Nasdaq Stockholm. Saniona partnered with Productos Medix of Mexico in 2016 for commercial rights in Mexico and Argentina, while retaining global rights to the proprietary combination product Tesomet.

The Phase 3 Viking Trial

The pivotal Phase 3 study was conducted by Medix in Mexico and read out in December 2018. Design: 372 obese adults, randomized 1:1:1 to placebo, 0.25 mg tesofensine, or 0.50 mg tesofensine once daily. Treatment duration was 24 weeks after a 2-week run-in, followed by a 12-week follow-up. Primary outcome was change in body weight versus placebo.

Results: both doses achieved statistically and clinically significant weight loss versus placebo. Average weight loss in the active arms was approximately 10 percent over 24 weeks, with more than half of patients losing more than 10 percent of baseline body weight. Reductions were reported in abdominal and visceral fat, blood cholesterol, triglycerides, and insulin. The safety profile was characterized as favorable, with increased heart rate as the most consistent adverse signal (approximately 7.4 bpm elevation versus placebo). The combined clinical safety database across all tesofensine trials at the time of filing contained approximately 1,600 patients.

The Mexican Regulatory Saga

Medix filed a New Drug Application with COFEPRIS in December 2019. The application sat with the agency through the COVID period. In February 2023, COFEPRIS's technical committee on new molecules (Comité de Moléculas Nuevas) issued a favorable opinion for tesofensine in obesity. Saniona's communications at the time characterized this opinion as a positive technical step, not a final marketing authorization.

In November 2024, Saniona announced that COFEPRIS had not granted approval and that Medix was entering into dialogue with the agency. The press release stated that the agency's decision appeared not to be based on the full data package as submitted. As of mid-2026, no approval has been issued in any major jurisdiction, and tesofensine is not commercially available as a marketed pharmaceutical product.

The Tesomet Strategic Pivot

Saniona's commercial priority is Tesomet, a fixed combination of tesofensine plus the beta-blocker metoprolol. Metoprolol offsets the heart rate increase produced by tesofensine alone. Tesomet is being developed not for general obesity but for two rare-disease indications:

• Prader-Willi syndrome (PWS): a genetic disorder characterized by severe hyperphagia (uncontrollable hunger) and treatment-resistant obesity. Tesomet showed positive Phase 2a results in PWS (NCT03149445), including reductions in weight, BMI, and hyperphagia in a small adolescent cohort.
• Hypothalamic obesity (HO): severe obesity following hypothalamic injury, typically from craniopharyngioma resection or other tumor treatment. Tesomet showed statistically significant reductions in weight, waist circumference, and glycemic control versus placebo in the Phase 2a study (NCT03845075). Patients in both PWS and HO typically do not respond to lifestyle modification.

Phase 2b/3 studies for both orphan indications have been in planning. Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is the only currently approved drug for select monogenic obesity disorders and would be the main reference comparator if Tesomet reaches the market.

Tesofensine is a non-selective monoamine reuptake inhibitor. It binds the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT) in the synaptic cleft, blocking the reuptake of all three monoamine neurotransmitters back into the presynaptic neuron. The result is elevated synaptic concentrations of dopamine, norepinephrine, and serotonin.

In the context of appetite regulation, all three monoamines contribute:

• Dopamine drives reward-based food seeking. Elevated synaptic dopamine in mesolimbic circuits reduces the reinforcement value of food.
• Norepinephrine increases sympathetic tone, modestly raising resting metabolic rate and reducing hunger signals.
• Serotonin is the most established satiety neurotransmitter. Elevated synaptic 5-HT in hypothalamic feeding circuits reduces food intake.

A 2024 paper from the Gutierrez group at the National Polytechnic Institute in Mexico characterized a circuit-level effect that may be central to tesofensine's appetite suppression: the compound silences GABAergic neurons in the lateral hypothalamus (LH). LH GABA neurons are part of the circuitry that drives food seeking and consummatory feeding. Their silencing is consistent with reduced motivation to eat.

Tesofensine is a phenyltropane, the same chemical family as cocaine and several psychostimulants. The structural similarity has not translated to abuse-liability findings consistent with stimulants in published trials, partly because of its slow pharmacokinetics: oral absorption is gradual and the plasma half-life is long (sufficient to support once-daily oral dosing without titration). Slow rise and slow clearance reduce the abrupt monoamine surges that drive reinforcement.

The metabolic-rate component is small. Most of the weight-loss effect in trials is driven by reduced food intake, not by increased energy expenditure.

Clinical trial outcomes (TIPO-1 Phase 2 and Viking Phase 3):

• 0.25 mg/day: meaningful weight loss versus placebo, magnitude lower than 0.5 mg
• 0.5 mg/day: approximately 10 percent weight loss at 24 weeks
• 1.0 mg/day (TIPO-1 high-dose arm): approximately 10.6 percent weight loss at 24 weeks
• More than 50 percent of patients on active drug lost more than 10 percent of baseline body weight in Phase 3
• Reductions in abdominal/visceral fat, subcutaneous fat, blood cholesterol, triglycerides, fasting insulin
• Reduced appetite and food craving as the primary mechanism
• Resting heart rate increased by approximately 7.4 bpm

Cognitive and CNS effects (legacy data from Alzheimer's/Parkinson's trials):

• Modest pro-dopaminergic effects (consistent with the original CNS targeting)
• Some studies reported small improvements in cognitive endpoints in Parkinson's populations, but the effects were not large enough to support that indication

Tesomet effects in orphan disorders (Phase 2a):

• Prader-Willi syndrome: reductions in body weight, BMI, and hyperphagia in a small adolescent cohort at 0.25 mg/day
• Hypothalamic obesity: statistically significant reductions in body weight, waist circumference, and glycemic control versus placebo

User-level reports are not relevant for tesofensine because the drug is not commercially available. There is no significant gray-market vendor population the way there is for research peptides. Tesofensine intake outside formal clinical trials is uncommon and not characterized.

Phase 3 trial doses were 0.25 mg and 0.50 mg once daily, taken orally as tablets, over 24 weeks, in adults with obesity. 0.5 mg is the dose proposed for marketing authorization for general obesity. No titration is required because of the long pharmacokinetic profile.

Tesomet Phase 2 doses for orphan indications: 0.125 mg/day, 0.25 mg/day, and 0.5 mg/day have been tested in different protocols. In Prader-Willi syndrome (an adolescent population), 0.25 mg/day showed a favorable benefit/tolerability profile.

Higher doses (1.0 mg/day in TIPO-1) produced marginally greater weight loss with proportionally greater adverse-effect burden, particularly in heart rate and blood pressure. The 0.5 mg dose was selected for Phase 3 as the optimal efficacy/tolerability balance.

Tesofensine is not available by prescription in any jurisdiction as of mid-2026. There is no compound-specific consumer protocol because there is no consumer-accessible regulatory pathway. The doses described above are from controlled clinical trials and should be considered in that research context only.

Phase 3 Viking trial safety profile characterized tesofensine as "well tolerated" overall, with low rates of serious adverse events. The recurring adverse signals across the development program:

• Increased heart rate (approximately 7.4 bpm versus placebo), the most consistent and dose-related finding. This is the basis for combining tesofensine with metoprolol in Tesomet.
• Increased blood pressure in a subset of patients, mechanistically expected from norepinephrine reuptake inhibition.
• Insomnia and sleep disturbance, consistent with elevated CNS catecholamine tone.
• Dry mouth, common with monoamine-active drugs.
• Constipation.
• Mood changes in a minority of patients: irritability, anxiety, or low mood. The dopaminergic effect makes mood-related monitoring appropriate.

Theoretical and population-specific concerns:

• Cardiovascular risk: the historical experience with monoamine-active anti-obesity drugs (sibutramine was withdrawn in 2010 for cardiovascular safety reasons) is the dominant reason for the regulatory caution that has slowed tesofensine's approval pathway. The Phase 3 trial did not demonstrate the kind of cardiovascular event signal that triggered the sibutramine withdrawal, but the patient population was relatively small and short in duration.
• Drug interactions: tesofensine interacts with MAO inhibitors (risk of hypertensive crisis and serotonin syndrome), SSRIs and SNRIs (additive serotonergic effect), other monoamine-active drugs, and sympathomimetics. These interactions have not been the subject of dedicated published clinical interaction studies, but the mechanism predicts them.
• Abuse liability: the phenyltropane chemical family is structurally related to cocaine, which raises the question of whether tesofensine has reinforcing properties. Published data does not support significant abuse potential at the proposed therapeutic dose, primarily because of the slow pharmacokinetic profile. Higher doses and atypical routes have not been formally studied for abuse liability.
• Pregnancy and pediatrics: no human reproductive toxicity data. The Tesomet PWS development includes adolescent patients under formal trial oversight, which should not be extrapolated to general pediatric use.
• Discontinuation effects: monoamine reuptake inhibitors as a class can produce discontinuation symptoms (fatigue, mood drop, return of appetite). Tesofensine-specific discontinuation has not been characterized in detail.

Tesofensine sits in a different mechanistic class from the peptide-based obesity drugs that dominate the current market. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide (dual GIP/GLP-1), retatrutide (triple GLP-1/GIP/glucagon)) deliver larger weight loss (15 to 22 percent for the newer agents) but are injectable peptides with their own side-effect profile dominated by gastrointestinal effects. Tesofensine offers an oral, non-titrated alternative with a lower weight-loss magnitude and a CNS-cardiovascular side-effect profile rather than a GI one.

The pairing tesofensine plus a GLP-1 agonist has not been studied in any controlled trial. The two mechanisms are non-overlapping: monoamine reuptake inhibition targets central appetite and reward circuits, GLP-1 agonism targets gastric emptying and satiety hormones. Theoretical additivity is plausible but unstudied, and the combined cardiovascular and GI burden has not been characterized.

The pairing with setmelanotide (Imcivree, MC4R agonist) is conceptually related because both target hypothalamic obesity pathways. Setmelanotide is approved for specific monogenic obesity disorders (POMC, LEPR, PCSK1 deficiencies and Bardet-Biedl syndrome) and is in trials for hypothalamic obesity following hypothalamic injury, the same indication Tesomet targets. The two drugs would be competitors rather than complements if both reach market in HO.

Tesomet itself is already a stack: tesofensine plus metoprolol. Metoprolol is a cardioselective beta-1 blocker used to control tesofensine's tachycardia signal. This combination is the proprietary Saniona product, not an off-label combination.

The pairing tesofensine should be avoided with is any monoamine oxidase inhibitor (MAOI), currently or recently used. The interaction risk is hypertensive crisis and serotonin syndrome. The minimum recommended washout for MAOIs before adding any monoamine reuptake inhibitor is two weeks; for irreversible MAOIs the washout is longer.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.